BDTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BDTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Black Diamond Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.11 Mil. Black Diamond Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $22.19 Mil. Black Diamond Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $116.74 Mil. Black Diamond Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.22.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Black Diamond Therapeutics's Debt-to-Equity or its related term are showing as below:
During the past 7 years, the highest Debt-to-Equity Ratio of Black Diamond Therapeutics was 0.24. The lowest was 0.03. And the median was 0.18.
The historical data trend for Black Diamond Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Black Diamond Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Debt-to-Equity | Get a 7-Day Free Trial | - | 0.03 | 0.15 | 0.24 | 0.22 |
Black Diamond Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Debt-to-Equity | Get a 7-Day Free Trial | 0.24 | 0.28 | 0.33 | 0.19 | 0.22 |
For the Biotechnology subindustry, Black Diamond Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Black Diamond Therapeutics's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Black Diamond Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (3.113 | + | 22.185) | / | 116.736 | |
= | 0.22 |
Black Diamond Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (3.113 | + | 22.185) | / | 116.736 | |
= | 0.22 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Black Diamond Therapeutics (NAS:BDTX) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Black Diamond Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Biotech Growth N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Ra Capital Nexus Fund, L.p. | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ali Behbahani | director, 10 percent owner | 5425 WISCONSIN AVE, CHEVY CHASE MD 20815 |
Peter Kolchinsky | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ra Capital Management, L.p. | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ra Capital Healthcare Fund Lp | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
David M. Epstein | director, officer: See Remarks | OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747 |
Sergey Yurasov | officer: CHIEF MEDICAL OFFICER | C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310, SEATTLE WA 98102 |
Elizabeth Buck | officer: CHIEF SCIENTIFIC OFFICER | C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142 |
Erika Jones | officer: SEE REMARKS | C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142 |
Fang Ni | officer: SEE REMARKS | C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142 |
Biotech Ag Bb | 10 percent owner | SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200 |
Wendy L Dixon | director | |
Mark A. Velleca | director | 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709 |
Brent Hatzis-schoch | officer: See Remarks | C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By Marketwired • 08-11-2023
By Marketwired • 10-04-2023
By Value_Insider Value_Insider • 11-08-2022
By Marketwired • 06-27-2023
By sperokesalga sperokesalga • 05-09-2023
By Marketwired • 11-06-2023
By sperokesalga sperokesalga • 06-02-2023
By sperokesalga sperokesalga • 04-17-2023
By Value_Insider Value_Insider • 12-19-2022
By PurpleRose PurpleRose • 08-03-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.